Yu‐Han Alice Hsu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Yu‐Han Alice Hsu has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Cheng-Chen Eric Lan
Department of Dermatology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan
2 shared publications Cheng‐Che E. Lan
Department of Dermatology Kaohsiung Medical University Hospital Kaohsiung Taiwan
1 shared publication- Huei-Jing Wang
Department of Dermatology Kaohsiung Medical University Hospital, Kaohsiung Medical University Kaohsiung Taiwan
1 shared publication - Kuan-Yu Chu
Department of Dermatology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan; Department of Dermatology, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
1 shared publication - Sheng‐Yiao Lin
Department of Dermatology Kaohsiung Medical University Hospital Kaohsiung Taiwan
1 shared publication Shu‐Mei Huang
Department of Dermatology, College of Medicine Kaohsiung Medical University Kaohsiung Taiwan
1 shared publication
Latest Publications
- Open Access
- 13 April 2026
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 106
Concurrent Drug-induced Rowell Syndrome and Acute Generalized Exanthematous Pustulosis
- 13 April 2026
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 106
Open AccessConcurrent Drug-induced Rowell Syndrome and Acute Generalized Exanthematous Pustulosis
- 20 November 2025
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 393 (20) , 2035
Cutaneous Metastases from Breast Carcinoma
- 20 November 2025
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 393 (20) , 2035
Cutaneous Metastases from Breast Carcinoma
- Open Access
- 12 August 2025
- Published by Wiley in The Kaohsiung Journal of Medical Sciences
- Vol. 42 (1) , e70083
Disease Modification of Pustular Psoriasis by Secukinumab: A 20‐Year Follow‐Up of Von Zumbusch‐Type Generalized Pustular Psoriasis With Evolution Into Annular Pustular Psoriasis—A Case Report
- 12 August 2025
- Published by Wiley in The Kaohsiung Journal of Medical Sciences
- Vol. 42 (1) , e70083
Open AccessDisease Modification of Pustular Psoriasis by Secukinumab: A 20‐Year Follow‐Up of Von Zumbusch‐Type Generalized Pustular Psoriasis With Evolution Into Annular Pustular Psoriasis—A Case Report
- Open Access
- 2 August 2023
- Published by Wiley in The Kaohsiung Journal of Medical Sciences
- Vol. 39 (10) , 1038-1044
The effect of dipeptidyl peptidase‐4 inhibitor on incidence and clinical course in bullous pemphigoid patients in a tertiary medical center
Several studies have reported an association between dipeptidyl peptidase 4 inhibitor (DPP4i), a commonly prescribed second‐line oral antihyperglycemic drug, and bullous pemphigoid (BP). However, the benefits of DPP4i withdrawal in patients with BP remain controversial. This study primarily aimed to evaluate the clinical severity of DPP4i‐associated BP by comparing it to those without Type 2 diabetes mellitus (DM). The secondary objective was to determine whether cessation of DPP4i is necessary for all patients with BP. This retrospective case–control study included 83 patients. The participants were divided into three groups according to their diabetic status and the status of discontinuance or continuance of DPP4i. The 12‐month follow‐up of the monthly dosage of systemic steroids per body weight (kg) and the percentage of systemic steroid off‐therapy in these participants were recorded since the diagnosis of BP. Compared to patients with BP without DM, the 1st, 3rd, and 12th systemic prednisolone doses were significantly lower in the DPP4i group (p = 0.01684, 0.02559, and 0.009336, respectively). The 12th systemic prednisolone dose was significantly lower in patients who discontinued DPP4i (p = 0.0338). Nevertheless, several spontaneous remissions with systemic steroid off‐therapy were also noted in the DPP4i‐continuance group within 12 months of follow‐up. This article supports the favorable impact of DPP4i withdrawal in patients with BP and shows that DPP4i may incite or aggravate BP, resulting in a milder disease course.
- 2 August 2023
- Published by Wiley in The Kaohsiung Journal of Medical Sciences
- Vol. 39 (10) , 1038-1044
Open AccessThe effect of dipeptidyl peptidase‐4 inhibitor on incidence and clinical course in bullous pemphigoid patients in a tertiary medical center
Several studies have reported an association between dipeptidyl peptidase 4 inhibitor (DPP4i), a commonly prescribed second‐line oral antihyperglycemic drug, and bullous pemphigoid (BP). However, the benefits of DPP4i withdrawal in patients with BP remain controversial. This study primarily aimed to evaluate the clinical severity of DPP4i‐associated BP by comparing it to those without Type 2 diabetes mellitus (DM). The secondary objective was to determine whether cessation of DPP4i is necessary for all patients with BP. This retrospective case–control study included 83 patients. The participants were divided into three groups according to their diabetic status and the status of discontinuance or continuance of DPP4i. The 12‐month follow‐up of the monthly dosage of systemic steroids per body weight (kg) and the percentage of systemic steroid off‐therapy in these participants were recorded since the diagnosis of BP. Compared to patients with BP without DM, the 1st, 3rd, and 12th systemic prednisolone doses were significantly lower in the DPP4i group (p = 0.01684, 0.02559, and 0.009336, respectively). The 12th systemic prednisolone dose was significantly lower in patients who discontinued DPP4i (p = 0.0338). Nevertheless, several spontaneous remissions with systemic steroid off‐therapy were also noted in the DPP4i‐continuance group within 12 months of follow‐up. This article supports the favorable impact of DPP4i withdrawal in patients with BP and shows that DPP4i may incite or aggravate BP, resulting in a milder disease course.